Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bvt.115959. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 13/20 | 0.96 |
| ▸ | ADORA2B | P29275 | 12/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bvt.115959 SCHEMBL990077 | 0.98 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL13863558 | 0.98 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL13224547 | 0.98 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL13224527 | 0.98 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL12012980 | 0.98 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL24838605 | 0.98 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL990075 | 0.98 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8622034 | 0.88 | ADORA2A (0.82) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8622040 | 0.88 | ADORA2A (0.82) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL2777661 | 0.88 | ADORA2A (0.82) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131651-A1 | Synthesis of 2-substituted adenosines | CBT DEVELOPMENT LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1694691-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005056571-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131651-A1 | Synthesis of 2-substituted adenosines | ADORA3, NT5C2, RNGTT | ADORA2A 16/4885ADORA2B 11/4885ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.